Kolling Institute NEWS May 2026
Transforming cancer care across NSW
Page 3
Page 4
Page 10
Reducing poor value osteoarthritis care
Philanthropy strengthening research pipeline
Northern Sydney Local Health District
WWW.KOLLINGINSTITUTE.ORG.AU
MESSAGE FROM THE ACADEMIC DIRECTOR
I am pleased to present this edition of Kolling NEWS which offers an insight into the latest specialised research activity and impact across the institute. It has been an encouraging few months at the Kolling with investigators securing significant financial support, and a wealth of innovative and translational progress being made. Behind the headlines, a large amount of work is underway to finalise the Kolling’s next five-year research strategy and plan. I would like to thank the many people who have shared their time and experience to develop the strategy and ensure every researcher is in the best position to progress their work and extend their reach. Pleasingly, researchers have been awarded a $3.75 million grant from the Cancer Institute NSW to implement liquid biopsies into routine cancer care across New South Wales. Led by Professor Anthony Gill, the program aims to replace invasive procedures with a liquid biopsy to enable earlier detection, personalised treatment, and better monitoring of cancer outcomes. I was thrilled to announce five early to mid career researchers will share nearly $40,000 through the Skipper Jacobs Charitable Trust to support international travel and career development. The funding will enable recipients to present their research, build global partnerships and strengthen the Kolling’s
international profile across fields including renal health, cancer, osteoporosis, osteoarthritis and rehabilitation following spinal cord injury. I would like to thank the Skipper family for their generous support of our early and mid-career investigators and the NORTH Foundation. Our researchers, led by Professor Sarah Glastras, are launching a project to transform pregnancy care in Australia through early identification and treatment of gestational diabetes. Funded by the Balnaves Foundation, the project will look to improve health outcomes
The University of Sydney and the Kolling Institute have launched the BRIDGE program, a $1.3 million initiative to improve treatment for patients with one of the most aggressive forms of bowel cancer. Using precision medicine approaches including liquid biopsies, Professor Mark Molloy hopes to better understand treatment resistance and develop new, more effective therapies. Personally, I have just returned from a trip working with colleagues from NASA and other space agencies where MuscleMap collaborators delivered a panel presentation at the Spaceflight Human Optimization and Performance Summit at the Johnson Space Center in Houston, Texas. We shared the latest collaborative findings from the MuscleMap program–the AI powered imaging tool to rapidly assess muscle health. The program will be broadly applied to spaceflight and elite sport, while also supporting the diagnosis and treatment of major musculoskeletal and neurological conditions. I would like to thank the Helena Charitable Foundation for their generous support of our growing MuscleMap program, worldwide. Professor James Elliott
for both mothers and babies. Investigators have secured a
$2.6 million grant to reduce low value care for people with knee osteoarthritis by promoting evidence based treatments. Led by Dr Jillian Eyles and Professor David Hunter, the project will support GPs and physiotherapists to avoid unnecessary scans and reduce the growing burden of osteoarthritis on Australia’s health system. A large international study, led by Professor Lisa Harvey and A/Professor Joanne Glinsky, has found that increasing rehabilitation intensity soon after spinal cord injury does not improve recovery, function or quality of life. The findings suggest the current approach is achieving the best possible results, reassuring patients they don’t need extra costly therapy to maximise recovery.
2
KOLLINGNEWS | MAY 2026
Funds to deliver game-changing approach to cancer screening and treatment
“They will inform treatment approaches after surgery to determine if radiotherapy or
Royal North Shore Hospital oncologist and leading University of Sydney researcher Professor Nick Pavlakis has welcomed the funding boost, saying liquid biopsies will deliver wide-ranging benefits.
Researchers at the Kolling Institute have been awarded significant funding to embed an innovative technique for cancer diagnosis and treatment into healthcare across New South Wales. Delivered by the Cancer Institute NSW, the $3.75 million Translational Program Grant has been awarded to University of Sydney researcher Professor Anthony Gill to test and implement liquid biopsies into routine cancer care. Liquid biopsies involve a simple blood test to identify and monitor cancers, and are expected to revolutionise treatment approaches and outcomes for all cancers. Based at Royal North Shore Hospital and the Kolling Institute, Professor Gill said liquid biopsies are a very new and exciting technique which will replace invasive surgeries and tissue biopsies for some patients. “The great majority of trials of new cancer treatments around the world now include a liquid biopsy component to track the response of the tumours. It is now important to bring capability for this new testing to NSW,” he said. “This new technology can pick up small amounts of DNA shed by cancer in the blood, providing a valuable screening tool and crucial information to guide treatment. “Liquid biopsies are not only used in the diagnosis of cancer, but to assess whether any cancer has been left behind following surgery, if a cancer has returned and if a tumour is not responding to chemotherapy.
chemotherapy are also needed to prevent a cancer returning. We know that if tiny fragments of DNA from the cancer are still in the blood after surgery, then more treatment is needed.
Professors Nick Pavlakis and Anthony Gil
“Liquid biopsies for cancer are not just one test. It is a combination of different tests,” he said. “Some are designed as screening tests, some are designed to predict response to treatment, some are designed to monitor for recurrence. Each different type of test has a different role at different stages of diagnosis and treatment.”
Importantly, the innovative technique will deliver broad support for remote and disadvantaged communities. “Patients from rural and isolated communities often travel hundreds of kilometres for biopsies to diagnose their cancer, or to track their progress. With this technique, a simple blood test can be taken close to home and sent to our unit for testing,” he said.
3
WWW.KOLLINGINSTITUTE.ORG.AU
National research program to increase access to high-quality osteoarthritis care
Researchers at the Kolling Institute have received a remarkable $2.6 million Medical Research Future Fund grant for a large-scale project to reduce low-value care for people living with knee osteoarthritis. With millions of Australians living with the painful condition, osteoarthritis costs the health system an estimated $4.3 billion each year. Led by Dr Jillian Eyles and Professor David Hunter, the project will test a practical approach to help health professionals provide the right care at the right time.
Although clinical guidelines recommend education, exercise and weight management as the most effective first steps, two in three Australians with osteoarthritis do not receive this care. Instead, they’re referred for unnecessary scans and arthroscopic knee procedures with little benefit and potential harm. This study will support GPs and physiotherapists in areas of Australia where unnecessary procedures are more common, giving them tools and practical support to confidently deliver evidence-based care. Education, resources and support will be offered, while surgery rates, imaging and specialist referrals will be tracked.
Dr Jillian Eyles said the project is about improving both patient experience and health outcomes. “We know that for many people, the journey into unnecessary osteoarthritis care starts with a scan. That scan can lead to referrals and procedures that don’t necessarily improve pain or function,” Dr Eyles said. “We believe we can reduce the burden of painful knee osteoarthritis in Australia by making some simple, practical changes to how it is diagnosed and managed. If we can support clinicians to feel confident diagnosing knee osteoarthritis without unnecessary imaging –and support patients to understand and feel comfortable with that approach–we can begin to interrupt that pathway.”
4
KOLLINGNEWS | MAY 2026
Professor David Hunter said the heart of the project lies in restoring confidence in evidence- based care. “Exercise, education and weight management are proven to help people live well with osteoarthritis. Yet too often, these are overlooked in favour of quick fixes that don’t address the underlying issue,” Professor Hunter said. “This study is about backing our clinicians with the tools they need to deliver best-practice care and empowering patients to expect and ask for that care. If we get this right, we won’t just reduce unnecessary procedures; we’ll improve mobility, reduce pain and help people stay active and independent for longer.” The grant success was made possible by early philanthropic seed funding from the Girgensohn Foundation. Dr Eyles said we are deeply grateful to the Girgensohn Foundation and the NORTH Foundation for believing in this approach. “Their support helped us build the foundations needed to attract this national funding. It’s a powerful example of how philanthropy can deliver change at scale.” To support osteoarthritis research, contact the NORTH Foundation.
Dr Jillian Eyles
Professor David Hunter
5
WWW.KOLLINGINSTITUTE.ORG.AU
Lessons learned in space to improve our muscle health at home
With the world’s attention on spaceflight following the historic Artemis II mission to the Moon, our researchers at the Kolling Institute are supporting the expert team working to protect the health of astronauts before, during and after their trips into space. The institute’s Academic Director,
Professor James Elliott has returned from a trip to the
Johnson Space Center in Houston, Texas, where he presented at the Spaceflight Human Optimization and Performance Conference. Insights from this work will assist NASA as it prepares for sustained
With astronauts exposed to extreme conditions including micro-gravity, the group hopes to increase our understanding of spinal stability, muscle health and impaired movement. This will be crucial to reduce the risks to crew safety, the continuity of missions and post-landing health and wellbeing. Professor Elliott is keen to work with collaborators from around the world.
lunar expeditions and long- duration missions to Mars.
“It is a very exciting time to be involved and I’m thrilled to be part of the team dedicated to extending of our knowledge of the unique health challenges of spaceflight and how to minimise the risks,” he said. The group will draw on learnings from the MuscleMap program, a world first radiology tool designed to measure muscle health. The program is being developed with support from more than 60 collaborators worldwide, including co founders Dr Ken Weber and Dr Eddo Wesselink from Stanford University, Professor Elliott and Associate Professor Marnee McKay from the University of Sydney. By combining MuscleMap with emerging technologies such as liquid biopsy, there is significant potential to redefine diagnostic frontiers, not only for cancer, but for many diseases and conditions that influence human health and wellbeing.
Professor James Elliott
6
KOLLINGNEWS | MAY 2026
Professor Elliott with Dr Danielle Anderson Musculoskeletal Medicine and Rehabilitation Lead–Space Medicine Operations, NASA
Revolutionary approach to mapping muscle health The MuscleMap tool will support the diagnosis and treatment of musculoskeletal and neurological conditions, including osteoporosis, cancer, Parkinson’s disease, sarcopenia and frailty. An estimated 4 billion people “Currently, we can identify these changes by manually assessing CT and MRI scans, but the process takes many hours, making it unfeasible,” he said.
The long-term vision is for MuscleMap to operate as a true push-button system–where a clinician will perform a scan, and within minutes receive a comprehensive set of muscle- health metrics that can easily be interpreted in a clinical context. MuscleMap will be applied to rehabilitation, disease assessment and management, elite sports health and optimal performance.
“MuscleMap however, will use available MRI and CT scans and artificial intelligence, to detect changes in muscle health rapidly and accurately. “From athletes to astronauts and the general population, MuscleMap will accurately inform the journey from injury to repair, recovery and return to physical activity, informing personalised strategies to develop healthier muscle mass and improve general health and wellbeing.”
worldwide are impacted by these conditions, with healthcare costs in Australia alone set to triple to $21 billion by 2033. MuscleMap will help detect disease earlier, enabling timely treatment and significantly better health outcomes. Professor Elliott said we know these conditions often lead to a rapid and steady decline in muscle health, and this decline is evident by an increase in fat deposits in the muscles and the loss of muscle fibres.
7
WWW.KOLLINGINSTITUTE.ORG.AU
Camilla Berke with Professor Jose Antonio Lopez Escamez
Unique expertise draws patients from across the world For many people li ving with Meniere’s disease, there’s a tremendous sense of isolation and so I feel very fortunate to be able to come here and be part of this research.”
would lose my medical clearance and would no longer be able to fly and continue my career,” she said. “Being a pilot was part of my identity and such an important part of my life. I loved being able to travel all over the place, and meet a lot of people, so it really has been difficult.” With limited information about the rare condition, Camilla turned to community Facebook groups for support and guidance. It was through these groups that she heard about Professor Lopez- Escamez and his leading research into Meniere’s disease. Camilla reached out to the eminent academic and was invited to take part in the research program based at the Kolling Institute. She underwent genetic, hearing and targeted testing, hoping to discover more about the condition and help progress the vital research. “I would fly anywhere to learn more about the condition,” she said. “It’s so important to be able to speak to someone who understands,
plenty of challenges accessing the latest, accurate information – that’s why 58 year old Camilla Bjerke flew more than 15,000 kilometres to Sydney to meet with the Kolling Institute’s Professor Jose Antonio Lopez-Escamez. The professor heads the Meniere’s Disease Neuroscience Group, a talented group of investigators working to uncover the key drivers of the disease, and develop new and effective treatments to help manage the disabling condition. Meniere’s disease is a rare inner ear disorder, defined by sensorineural hearing loss, vertigo and roaring tinnitus. For Camilla, who has worked as a pilot in Norway for more than 30 years, her diagnosis was devastating. “For me, it was twofold. I had to accept that I had this condition, with constant dizziness, vertigo and hearing loss, but also, that I
Camilla said it has been valuable to hear about the specific subgroups of the disease, information which she says is not widely known or understood. Camilla hopes that by taking part in the research she may also be helping her family and others in the same situation. “I wouldn’t be surprised if my condition has been inherited, so I would like to do what I can to help advance the research for my children too.” Professor Lopez-Escamez and his team at the Kolling are pursuing world-leading investigations into the genetic factors influencing the disease, and taking crucial steps towards the development of game- changing gene therapy, which is expected to revolutionise treatment for the condition over the next decade. To support or join the research program, contact: meniereaustralia@sydney.edu.au
8
KOLLINGNEWS | MAY 2026
Research to offer generational change
Kolling Institute investigators are launching exciting research to transform pregnancy care in Australia through early identification and treatment of gestational diabetes, improving outcomes across two generations. The research has been made possible by generous funding from the prestigious Balnaves Foundation, which says it is proud to partner with the Kolling’s Professor Sarah Glastras to improve health outcomes for both mother and baby. The University of Sydney and Royal North Shore Hospital will also be key collaborators. One in six Australian women find their pregnancy journey disrupted by a diagnosis of gestational diabetes mellitus–a condition with serious risks including birth trauma, low blood sugar in newborns, and an increased risk of type 2 diabetes for both mother and child. It is the fastest growing type of diabetes in Australia, and contributes to a cycle of chronic disease. Building upon existing research, Professor Glastras and her team
will build, test and refine a risk prediction model to identify women most at risk and offer access to a tailored lifestyle intervention program. The model will use a simple blood test to spot early signs of gestational diabetes and then intervene before symptoms appear. Professor Glastras said this approach will deliver better health outcomes for mothers, such as increased muscle, steady blood sugar levels and reduced neonatal stress, while also reducing anxiety and improving engagement.
“Intervention at this critical stage in the lifespan will help lower rates of childhood obesity, improve maternal mental health, and prevent chronic health conditions in the next generation,” she said. “Importantly, it will reduce the risk of women and their babies developing type 2 diabetes. “Women identified as high-risk will not simply receive a diagnosis, through this project they will gain access to a tailored lifestyle program, shaped by multi-disciplinary care and cultural responsiveness. “The personalised support will help mothers stay healthy and give their babies the best start in life. “The program has the potential to lay the foundation for a new national standard in antenatal care. “We are very grateful for the philanthropic support from the Balnaves Foundation and we look forward to capturing more women with this condition and making life-long improvements to their health, and the health of their baby.”
Professor Sarah Glastras
9
WWW.KOLLINGINSTITUTE.ORG.AU
2026 Beryl and Jack Jacobs Travel Awards announced
A collection of five early-to-mid career researchers will share close to $40,000 in funding through the Skipper Jacobs Charitable Trust. The Skipper family has generously supported emerging research talent at the Kolling Institute for many years, providing invaluable travel and career opportunities. This year’s group has welcomed the chance to travel internationally, meet with research leaders and extend their research experience. The opportunities will strengthen global partnerships, while also raising the Kolling’s profile internationally. The 2026 Beryl and Jack Jacobs Travel Award recipients include:
Dr Matilda Longfield from the Renal Research Lab: travelling to Italy and the UK Through this opportunity, Matilda will attend the
Shejil Kumar from the Cancer Genetics Laboratory: travelling to Belgium and Melbourne Dr Kumar will travel to the
premier European bone conference in Belgium in 2027 to present details of his world-first clinical trial investigating the combined musculoskeletal benefits of bone-building medication and bone- targeted resistance exercise in postmenopausal women with osteoporosis.
2026 European Association for the Study of Diabetes conference in Milan which will explore the latest advancements in diabetes research, treatment and care. Matilda will also travel to
Leicester University in the UK for a two-week research placement to develop an exciting collaboration, learn new cutting-edge research skills, and develop new ideas for future academic pursuits. She is delighted to have received the award. “I was over the moon to discover that my application was successful. This is a significant investment in my research career and future that I feel honoured to have received.”
This award will also support a two-week laboratory visit to Monash University to conduct specialised experiments and strengthen collaborations between the Kolling and Monash in conducting innovative mechanistic research. He says the award is delivering a broad impact. “My supervisors saw the acceptance email before I did, and seeing their joy was such a lovely way to find out I had received the award,” he said.
10
KOLLINGNEWS | MAY 2026
Anh Pham from the Bowel Cancer and Biomarker Lab: travelling to Singapore and Malaysia Anh will travel to the
He said he is honoured to receive the award which came as a wonderful surprise. “It is a great opportunity to build international collaborations and develop advanced imaging approaches that support the translation of regenerative therapies into clinical practice,” he said. Helen Patterson from the John Walsh Centre for Rehabilitation Research: travelling to London and Kuala Lumpur
Human Proteome Organisation World
Congress in Singapore and the Metaproteomic Symposium in Malaysia, two of the leading international bowel cancer research conferences. The trips will support Anh’s
The award will allow Helen to attend two international conferences where she will present a workshop on rehabilitation after nerve transfer in tetraplegia at
research investigating an anti-diabetic agent, as a chemo-preventive therapy for colorectal cancer. Anh said the trips will be a great opportunity to present her work to a global audience, connect with world-leading researchers, and bring back cutting- edge insights. “Receiving this travel award is such an honour and I am incredibly grateful for the support,” she said. “Travelling to Singapore and Malaysia will be a career highlight, which will help me gain expert knowledge from proteomic world leaders and further my research here at Kolling. I am excited to represent Kolling Institute and our research.” Dingyuan Fan from the Osteoarthritis Clinical Research Group: travelling to Spain and Austria Dingyuan will present his research poster at the World Congress on
the World TetraHand Congress in London, and present at the International Spinal Cord Society’s 2026 Annual Scientific Meeting in Kuala Lumpur.
The meetings will help Helen share the results of her work and learn more about the research and treatment advances for people with spinal cord injury. This will help extend Helen’s studies on a more robust protocol for rehabilitation after nerve transfer surgery. “I felt lucky to have the opportunity to apply for a travel scholarship through the Kolling Institute, so was delighted when I found out that I was to be a recipient. “To be supported to travel overseas is a privilege and I am incredible grateful,” she said. These opportunities would not be possible without the financial boost delivered through the Skipper Charitable Trust. Academic Director Professor James Elliott would like to thank the Skipper family for their wonderful ongoing support of our early and mid-career investigators, and the NORTH Foundation for their continued support. “Their help is directly broadening the Kolling’s research expertise and impact,” he said.
Osteoarthritis in Spain in 2027. Dingyuan’s research uses biomarkers to investigate structural cartilage changes
following regenerative therapy, with a focus on improving the assessment of treatment response in osteoarthritis.
Following the conference, Dingyuan will visit Professor Felix Eckstein at Paracelsus Medical University in Austria. The trip will help build international collaborations and develop advanced imaging approaches to support the translation of regenerative therapies into clinical practice.
11
WWW.KOLLINGINSTITUTE.ORG.AU
Introducing BRIDGE: A life-changing gift advancing research and treatment for rare bowel cancer
The University of Sydney and the Kolling Institute have launched a groundbreaking research program to transform treatment for one of the most aggressive forms of bowel cancer. Supported by a $1.3 million philanthropic gift, the BRIDGE program offers new hope for patients with BRAFv600e mutated bowel cancer. This mutation, present in around 10 per cent of colorectal cancer cases, drives tumour growth and is associated with significantly poorer outcomes. While two targeted therapies– encorafenib and cetuximab–have been approved, many patients quickly develop resistance, leaving a critical gap in care. BRIDGE seeks to address this gap by uncovering why some patients respond well to treatment while others relapse, and by identifying new treatment strategies for relapsing disease. Patient, Gemma Farquhar, said this donation is deeply personal. “When I found out I had BRAF, carrying a poor prognosis, I felt like there was no future,” she said. “Knowing treatments are likely to fail, is a terrifying place to be. Research like BRIDGE gives people like me something–time, options and hope. It means scientists are looking ahead now, for the future.” Lead researcher Professor Mark Molloy said many patients feel they are running out of options. “Our work is dedicated to changing that,” he said.
Professor Nick Pavlakis, Gemma Farquhar, Professor Mark Molloy and Dr Mudy de Silva
BRIDGE is the first clinical study of its kind for BRAF mutated bowel cancer, using precision medicine approaches such as liquid biopsies to analyse tumour DNA from blood samples and track treatment response over time. Co lead investigator, eminent Royal North Shore Hospital oncologist, Professor Nick Pavlakis said advances in genomic technologies are opening new possibilities. “Liquid biopsies allow us to understand which treatments are most likely to benefit each patient,” he said. “It’s about matching the right treatment to the right patient at the right time.” The program will also explore the tumour’s immune environment, an area that remains largely unexplored in BRAF driven bowel cancers. By identifying immune cells within tumours and linking them to treatment outcomes, researchers hope to better understand why responses vary so widely.
In parallel, the team will grow patient derived tumour samples in the laboratory, creating organoids that closely mimic the cancer. These models will enable researchers to safely test potential drug combinations before they are considered for clinical use. Professor Molloy said BRIDGE represents a rare and powerful opportunity for translational research. “By combining laboratory science with clinical expertise, our findings can move quickly from the lab to benefit patients,” he said. “The program will also support and train the next generation of cancer researchers, strengthening a field that has historically received limited funding.” Ultimately, BRIDGE aims to deliver both immediate insights and long term breakthroughs - identifying the genetic and immune factors that drive treatment response, uncovering vulnerabilities in resistant tumours and providing renewed hope for patients with BRAF mutated bowel cancer.
12
KOLLINGNEWS | MAY 2026
Major study finds extra intensive training does not change outcomes following spinal cord injury
A landmark study led by researchers from the Kolling Institute has confirmed that stepping up rehabilitation soon after a spinal cord injury does not improve recovery or deliver significantly better outcomes. These important findings follow a phase 3 study involving 220 people across rehabilitation centres in Australia and Europe, including several leading Dutch and Flemish institutions. Researchers measured the impact of 10 weeks of additional motor training which involved 12 hours a week of extra intensive therapy on top of the usual inpatient rehabilitation. The results indicated no meaningful improvements in neurological recovery, functional independence, walking ability or quality of life immediately after the 10-week program or six months later. Study lead Professor Lisa Harvey said the result suggests the current level of specialised care already provides sufficient training intensity.
“We have confirmed that increasing training hours in the early days after an injury doesn’t enhance recovery.” she said. Professor Harvey welcomed the large-scale, international collaboration involved in the trial, saying it has delivered a definitive result. “Trials like this are not possible without the co-operation of so many different people,” she said.
“The successful completion of this trial shows what can be achieved when we combine forces.” “While all of us would like to see solutions and cures for people who experience a spinal cord injury, research in this field will only progress if we tease out what therapies do and don’t make a difference.” Co-lead, Associate Professor Joanne Glinsky said people with this type of injury can be reassured that they don’t need to chase costly and time-consuming intensive exercise programs to maximise their potential for recovery. “What they are currently receiving is just as good,” she said. “This means that any remaining disability is not because they didn’t work hard enough. We hope that this may offer patients some comfort and reassurance.” The findings have been published in the highly-respected Lancet Neurology.
Professor Lisa Harvey and A/Professor Joanne Glinsky
13
WWW.KOLLINGINSTITUTE.ORG.AU
Professor Ashley Craig, Dr Johnny Bourke, Dr Mohit Arora and Professor James Middleton)
International collaboration to offer mental health support after spinal cord injury
He says the project has the potential to transform models of support, shape clinical practice, and create meaningful impact on the lives of people with spinal cord injury worldwide. “This is a wonderful collaborative opportunity to bring together academics, researchers, healthcare professionals, and peer professionals with lived experience from Australia and the United Kingdom,” he said. “We will be working to co-design, implement and importantly, evaluate strategies to enhance the mental health and wellbeing of people with spinal cord injury. “This is an area where we hope to offer specific, relevant and proven strategies for support.”
In addition to the Australian and UK investigators, three consumer and charity organisations will join the project including representatives from Spinal Cord Injuries Australia, Back Up Trust-UK and the Spinal
Researchers from the Kolling Institute will partner with UK investigators on an exciting project to boost the mental health and wellbeing in people with a spinal cord injury. A generous philanthropic grant from Stoke Mandeville Spinal Research has paved the way for the research which will build on the resources developed for the Spinal Cord Injury Health Maintenance Tool. This tool is an online resource offering practical, evidenced-based and in-depth information for people with the disabling injury. Dr Mohit Arora from the John Walsh Centre for Rehabilitation Research is thrilled to lead the initiative, with support from fellow John Walsh researchers Professors Ashley Craig and James Middleton, and Dr Johnny Bourke.
Injuries Association UK. Dr Arora said this strong
collaboration reflects a shared commitment to improving the psychological wellbeing and quality of life of people with spinal cord injury through research translation, co-design, and cross- country knowledge exchange. “The project team is deeply grateful to Stoke Mandeville Spinal Research for funding this work, and to icare NSW for the foundational funding support for the development of the Spinal cord Injury Health Maintenance Tool,” he said.
14
KOLLINGNEWS | MAY 2026
15
WWW.KOLLINGINSTITUTE.ORG.AU
You can shape the future of healthcare Donate before 30 June to support medical research and innovation
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16Made with FlippingBook - professional solution for displaying marketing and sales documents online